7月22日，Arrowhead Pharmaceuticals盘前上涨8.64%，报84.0美元/股，成交额6.85万美元。
消息面上，公司公布旗下药物Plozasiran在两项关键临床试验Shasta-3和Shasta-4中分别实现79%和81%的中位甘油三酯降低率；同时该药物在高危患者群体中实现急性胰腺炎事件100%的风险削减，且未出现新的安全信号，安全性特征稳定。
Plozasiran此前已以商品名Redemplo获得欧盟上市许可，用于治疗家族性乳糜微粒血症综合征。此次多项积极数据同步发布，进一步拓宽了该药物在心血管代谢疾病领域的适应症前景。目前华尔街对ARWR的平均评级为"买入"，均值目标价为91.82美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.